Register for our free email digests:
Latest From Lederle Laboratories
Late-stage pipeline is dominated by follicle stimulating hormones, split between “biobetters” and biosimilars. Next-generation oxytocin antagonists are leading candidates for the next novel entities in infertility.
Watson’s merger with Actavis will create the world’s third-largest generic drug company, to be known as Actavis, with significant ex-U.S. market share, especially in the U.K., Nordic countries and Russia.
With the Actavis deal finalized, Watson achieves its long-sought goal of becoming a major international player in generics, and announces a new global management team to undertake the critical component: execution.
The agency issued a list of 364 ANDAs that will be deemed withdrawn unless the sponsor tells FDA it wishes to pursue them; it is a first step in clearing the backlog before generic drug user fees are enacted.
- Large Molecule
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Wilex Biotechnology GMBH
- Western Europe
- Parent & Subsidiaries
- Wilex AG
- Senior Management
Jan Schmidt-Brand, PhD, CFO
Andreas Pahl, Head, R&D
- Contact Info
Phone: (49) 89 41 31 38 0
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.